| Name | Title | Contact Details |
|---|
Wisconsin Rx is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Seabrook, we are dedicated to doing everything we can to make our customers successful. We are a contract manufacturer of medical devices specializing in surgical instruments, implants and devices for the orthopaedic market. In addition to the high
OSF HealthCare is a multi-state healthcare system, providing state-of-the-art, compassionate care to nearly 3 million people in the communities we serve, through 13 acute care facilities and two colleges of nursing. OSF HealthCare is proud to be among the nation`s leading innovators in the transformation of care for better health for our communities, consistently excellent patient experience and lower costs.
Confluence Health is an integrated, rural healthcare delivery system with two hospitals, multi-specialty care in more than 30 service lines and primary care in 12 communities across North Central Washington. Our 250+ physicians and 150+ advanced practice clinicians serve an area of approximately 12,000 square miles and cover nearly every corner of the region through specialty outreach. Confluence Health is dedicated to improving our patients` health by providing safe, high-quality care in a compassionate and cost-effective manner. Core Values • Our patients are the reason for our being, and their needs will drive all of our actions. • We will treat everyone with dignity,respect and compassion. • We will continue to innovate ways to improve the delivery of excellent, high value care. • We will measure successes and failures, and use the results to drive further improvement. • We will be a good neighbor in the communities we serve with donations of time, talent, and capital. • We will be ethical and accountable in all of our decisions and actions.
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.